Abstract: The present invention relates to compositions and methods for detection, analysis, and treatment of nucleic acids. In particular, the present invention relates to compositions and methods for generating and using hybridization probes.

Abstract: In order to conduct gene expression analysis of a number of genes in a number of cells, it has been necessary to separate cells, extract genes therefrom, amplify nucleic acids, and perform sequence analysis. However, separation of cells imposes damages on the cells, and it requires the use of an expensive system. Gene expression analysis in each cell can be carried out with high accuracy by arranging a pair of structures comprising a cell trapping section and a nucleic acid trapping section in a vertical direction to extract individual genes in relevant cells, synthesizing cDNA in the nucleic acid trapping section, amplifying nucleic acids, and analyzing the sequences using a next-generation sequencer.

Abstract: The present invention relates to the field of single nucleotide polymorphisms (SNPs) and uses therefore as a predictor of diseases and conditions. Specifically, the present invention provides methods and kits useful in determining whether a subject is at increased risk for developing a cardiovascular disease by screening for the presence of a SNP in the scavenger receptor class B type I (SR-BI) gene of a subject.

Abstract: The present invention related to a method of assaying ubiquitination in a sample by combining ubiquitin and two or more of E1, E2, E3 and a substrate protein in a sample under conditions suitable for ubiquitination to take place, exposing the sample with a labelled binding partner which is specific for the ubiquitin and measuring the amount of labelled ubiquitin bound to any one of the components in the sample, wherein one or more of the components in the sample comprises an immobilization tag which facilitates its immobilization onto a solid surface.

Abstract: Compositions and methods for determining circulating biomolecules before, during, and/or after treatment of a patient with an anti-cancer or anti-tumor drug (or putative drug) are described. Methods of treatments based on the compositions and methods described herein are also provided. Noninvasive methods and kits are provided for assessing the efficacy of an anti-cancer therapy for killing or damaging cancer cells. Embodiments are used to determine the cancer-killing efficacy of an anti-cancer drug in a patient, to optimize the selection of an anti-cancer drug for treatment of a patient, to adjust the dosage of an anti-cancer drug for treatment of a particular cancer in a patient and for identifying useful anti-cancer therapeutics for any one particular type of cancer.

Abstract: The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.

Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

Abstract: The invention provides a system, composition, and methods of using the systems and compositions for the analysis of a sample from a subject to accurately diagnose, prognose, or classify the subject with certain grades of or susceptibility to Barrett's esophagus. In some embodiments, the system of the present invention comprises a means of detecting and/or quantifying morphological features, the expression of protein, or the expression of nucleic acids in a plurality of cells and correlating that data with a subject's medical history to predict clinical outcome, treatment plans, preventive medicine plans, or effective therapies. In some embodiments, the invention relates to a method of classifying and compiling data taken from a cell sample from a subject analyzing the data, and converting the data from the system into a score by which a pathologist may calculate the likelihood that the subject develops cancer.

Abstract: The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.

Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Abstract: Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer.

Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.

Abstract: Disclosed are methods for identifying patients at increased risk of developing disseminated staphylococcal infection, which includes the steps of determining that the patient has a mutation in one or more genes selected from a MPDZ network gene, a CGNL1 network gene, a PRKRIR network gene, a MED26 network gene, a tight junction protein gene, or an immune modulator gene; and treating the patient for disseminated staphylococcal infection. Also disclosed are solid substrates and/or assays useful for carrying out the disclosed methods.

Abstract: The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.

Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

Abstract: The present invention relates to: a composition for diagnosing pancreatic cancer, containing a preparation for measuring the expression level of a protein or a gene thereof, and capable of being used for determining whether there is a risk of pancreatic cancer; a kit; and a method for diagnosing pancreatic cancer by using the same. The present invention can significantly predict or identify the risk of pancreatic cancer or a precancerous lesion of pancreatic cancer, the early diagnosis thereof and the extent of diseases thereof by providing a diagnostic marker of pancreatic cancer, and can be utilized in the research of pancreatic cancer oncogenesis. In addition, the diagnostic method of the present invention can provide simple and early diagnosis of pancreatic cancer from the blood and the like in a non-invasive manner.

Abstract: Non-invasive methods for detecting, predicting, and/or monitoring differential diagnosis of kidney transplant dysfunction in kidney transplant patients are described.

Abstract: The present invention is in the field of plant molecular biology and provides methods for production of high expressing seed-specific and/or seed-preferential promoters and the production of plants with enhanced seed-specific and/or seed-preferential expression of nucleic acids wherein nucleic acid expression enhancing nucleic acids (NEENAs) are functionally linked to the promoters and/or introduced into plants.

Abstract: The invention described herein relates to methods of screening for pro-inflammatory genes and anti-inflammatory genes which may be useful for treating an inflammatory disease, disorder, or otherwise abnormal condition, such as an inflammatory lung disease. The identified pro-inflammatory genes and anti-inflammatory genes may be used to produce pharmaceutical compositions for use in treating the inflammatory disease, disorder, or otherwise abnormal condition.

Abstract: This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has altered susceptibility to statin-induced myopathy.

Abstract: Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.

Abstract: Provided herein is technology relating to genotyping and particularly, but not exclusively, to methods for genotyping one or more organisms by genome sequencing.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.

Abstract: The present disclosure provides methods for diagnosing and treating anxiety disorders in female subjects. Diagnosis and treatment of such anxiety disorders are based, in part, on an analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in tissue collected from female subjects.

Abstract: Methods for detecting genomic rearrangements are provided. In one embodiment, methods are provided for the use of paired end tags from restriction fragments to detect genomic rearrangements. Sequences from the ends of the fragments are brought together to form ditags and the ditags are detected. Combinations of ditags are detected by an on-chip sequencing strategy that is described herein, using inosine for de novo sequencing of short segments of DNA. In another aspect, translocations are identified by using target specific capture and analysis of the captured products on a tiling array.

Abstract: A nucleic acid amplification and detection kit, including: a buffer storage assembly, including a buffer storage reservoir storing a buffer solution therein; a nucleic acid amplification assembly including a nucleic acid amplification reservoir storing one or more reagents therein and configured to receive a sample containing nucleic acid for amplification therein, wherein the buffer storage assembly is configured to couple with the nucleic acid amplification assembly to seal within the nucleic acid amplification reservoir the sample containing nucleic acid and amplification products of the amplification; and a test strip assembly including a lateral flow test strip disposed therein, the test strip assembly and the coupled nucleic acid amplification and buffer storage assemblies being configured to couple with one another and including one or more solution release components to release the amplification products from the nucleic acid amplification reservoir onto the lateral flow test strip for testing, and to

Abstract: The invention relates to improved alkaline phosphatases, pharmaceutical compositions comprising improved alkaline phosphatases and the use of improved alkaline phosphatases for preventing, treating or curing diseases.

Abstract: Embodiments of the invention are directed to methods of diagnosing eosinophilic esophagitis (EoE), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EoE, analyzing to obtain relatedness information relative to an EoE cohort and making a determination as to the EoE status of the subject, wherein an analysis indicating grouping with an EoE cohort or a quantitative score similar to that of an EoE cohort are indicative of EoE in the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EoE in a subject.

Abstract: The present disclosure provides a soft pastille containing turmeric extract as an active ingredient. The pastille is prepared using at least one gelling agent and at least one plasticizer in combination with pharmaceutically acceptable excipients, wherein the ratio of the gelling agent to the plasticizer is in a range of 1:2.5 to 1:3.3.

Abstract: A system for, and method of, recovering salt from fluid stream in a recycle loop of a flash separator has a desanding hydrocyclone located in the hot recycle loop of the flash separator; a first solids fluidization device located at the bottom end of the flash separator's brine column; a second desanding hydrocyclone arranged to receive a salt slurry stream created by the first solids fluidization device; and an accumulator located downstream of the second desanding hydrocyclone and having a second solids fluidization device located at its bottom end. Each solids fluidization device causes a motive fluid to exit the device in a swirling motion to fluidize the salt components contained in the resident fluid. The overflow from the second desanding hydrocyclone is the motive fluid for the brine column and a produced water, condensate water, or seawater stream is the motive fluid for the accumulator.

Abstract: An image acquisition unit (2020) acquires an analysis image. The analysis image is an image in which a plurality of cell nuclei in a lesion of a target person are captured. A feature-value calculation unit (2040) calculates the feature-value relating to the cell nuclei from the analysis image. An evaluation function acquisition unit (2060) acquires an evaluation function from an evaluation function storage unit (10). The evaluation function is a function with which prediction information is calculated based on the feature-value. The prediction information generation unit (2080) generates prediction information relating to a target person based on a feature-value, which has been calculated from an analysis image, and an evaluation function which has been acquired by the evaluation function acquisition unit (2060). The prediction information is information indicating a prediction of a prognosis of a disease of the target person or a prediction of malignancy of a disease of the target person.

Abstract: Disclosed is a method of determining KIR genotypes for one or more individuals in parallel, the method comprising: for each individual, amplifying the polymorphic exon sequences of the KIR genes, pooling the KIR amplicons, performing emulsion PCR followed by pyrosequencing in parallel to determine all the amplicon sequences present in the individual to determine which KIR alleles are present in the individual.

Abstract: Provided are a composition, a kit, and a method of predicting prognosis of ovarian cancer or a risk of recurrence of ovarian cancer. Provided are a composition for treating ovarian cancer or preventing recurrence of ovarian cancer and a method of screening a material for treating ovarian cancer or preventing recurrence of ovarian cancer. According to the present disclosure, prognosis or recurrence of ovarian cancer can be efficiently diagnosed, and a candidate material that can treat ovarian cancer or prevent recurrence of ovarian cancer can be efficiently screened.

Abstract: Methods comprising probing multiple targets in an H&E stained biological sample are provided. The methods include the steps of providing a hematoxylin and eosin stained biological sample containing multiple targets, optionally detecting H&E staining of the sample, removing the hematoxylin and eosin signals, and detecting additional features or targets in the biological sample. The detecting step may include performing the steps of binding at least one probe to one or more targets to the sample, detecting a signal from the probe and contacting the sample with a bleaching agent. The process of binding, detecting and bleaching may be iteratively repeated.

Abstract: The present invention relates generally to the detection or diagnosis of post-traumatic stress states in a subject, and provides methods, reagents, and kits useful for this purpose. Provided herein are biomarkers that are indicative of and/or diagnostic of post-traumatic stress states including PTSD.

Abstract: Non-invasive diagnostic methods for diagnosing bladder cancer are based on determining the expression level of one or more markers. The one of the markers comprises the IGF2 gene in a sample from the subject to be studied. Other suitable markers include MAGEA3, ANXAIO, AHNAK2, CTSE, CRH, KLF9, KRT20, POSTN, PPP1R14D, SLCIA6, TERT, ASAM, MCMIO, EBF1, CFH and MMP12 and possibly FOXM1, KIF20A, MELK, CDK1.

Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

Abstract: The invention provides a molecular affinity clamp. The architecture of the affinity clamp is modular with two biorecognition modules, each capable of binding a target motif. The first biorecognition module has a recognition domain that possesses inherent or natural specificity for the target motif. The second biorecognition module also has a recognition domain that binds the motif. The two biorecognition modules are tethered together either directly, e.g., via a peptide bond between the two modules, or indirectly, e.g., via a linker moiety or linker.

Abstract: Methods of treating metabolic and/or lipid disorders are provided comprising administering to a patient in need thereof a therapeutically effective amount of Nrg4, an Nrg4 variant, or a biologically active fragment thereof.

Abstract: The invention provides novel Wnt polypeptides that have improved production characteristics, solubility, systemic delivery, and tissue uptake, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth.

Abstract: Methods and compositions are disclosed for measuring low-abundance DNA variants from a complex mixture of DNA molecules. Embodiments of the methods allow for extremely sensitive detection and can distinguish true variants from sequencer misreads and PCR misincorporations.

Abstract: The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.

Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.

Abstract: A method includes generating, from an integrated oscillator circuit, an oscillating output signal and generating, by an integrated power amplifier (PA) circuit, an amplified oscillating output signal based on the oscillating output signal. The method further includes receiving, by integrated receiver amplifier circuit, an electron spin resonance (ESR) signal from biological samples that include a magnetic species and generating, by the integrated receiver amplifier circuit, an amplified ESR signal based on the received ESR signal. The method further includes receiving, by the integrated receiver amplifier circuit, an electron spin resonance (ESR) signal from magnetic nanoparticles that are loaded with drugs or attached to human cells.

Abstract: The invention is directed to fluorophore-containing compositions and configurations wherein proximity between the fluorophore and one or more protective agents (PAs) modifies the lifetime of fluorescent and/or dark states, their frequency of occurrence, and the total lifetime of fluorescence in order to appropriately modify the photophysical characteristics of the fluorophore. The invention is also directed to methods that utilize these compositions and configurations.

Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

Abstract: The present invention relates to agents and methods for screening, diagnosis and surveillance of cancer, in particular pancreatic cancer.

Abstract: The present disclosure provides compositions and methods for treating or reducing the risk of pancreatic cancer by administering compounds capable of inhibiting the expression or activity of RUNX3.

Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.